Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Eribulin in HER2 Negative Metastatic BrCa

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01827787
First received: April 3, 2013
Last updated: August 29, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)